Fig. 3.

NEO100-facilitated brain entry of trastuzumab prolongs survival of mice with intracranial HER2+ breast cancer. Mice were implanted intracranially with 4T1-HER2+ cells. Seven days later, the animals received a single round of treatment, consisting of intra-arterial (IA) NEO100 alone, intravenous (IV) trastuzumab alone, or a combination of the two. Some mice remained untreated (control). Shown is Kaplan-Meier survival plot with overall survival of animals in the different treatment groups and P values added.